Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 1, 2014, Pages 33-49

  Shoda, Lisl K M ^a   Woodhead, Jeffrey L ^a   Siler, Scott Q ^a   Watkins, Paul B ^a   Howell, Brett A ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

computational models; drug safety; drug induced liver injury; hepatotoxicity; mechanistic models

Indexed keywords

BENOXAPROFEN; BILE ACID; BUSPIRONE; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; ETOMOXIR; GLUCOSE; GLYCOGEN; HIGH MOBILITY GROUP B1 PROTEIN; NEFAZODONE; NILUTAMIDE; OLIGOMYCIN; OXYGEN; PARACETAMOL; ROTENONE; TRAZODONE;

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG INTOXICATION; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INNATE IMMUNITY; LIVER CELL; LIVER REGENERATION; LIVER TOXICITY; MALE; MATHEMATICAL MODEL; MITOCHONDRIAL TOXICITY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; RAT; SINGLE DRUG DOSE; TIME SERIES ANALYSIS; TOXIC HEPATITIS;

COMPUTATIONAL MODELS; DRUG SAFETY; DRUG-INDUCED LIVER INJURY; HEPATOTOXICITY; MECHANISTIC MODELS;

ANIMALS; BILE ACIDS AND SALTS; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNITY, INNATE; MITOCHONDRIA; MODELS, BIOLOGICAL; SOFTWARE;

EID: 84892368859     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1878     Document Type: Article

References (121)

1. Watkins PB,. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011; 89: 788-790.
2. Kaitin KI,. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010; 87: 356-361.
3. Adams CP, Brantner VV,. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25: 420-428.
4. Kola I,. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83: 227-230.
5. Olson H, Betton G, Robinson D, et al,. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32: 56-67.
6. Cohen DE, Anania FA, Chalasani N,. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97: 77C-81C.
7. Redfern WS, Bialecki R, Ewart L, et al,. Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle. J Pharmacol Toxicol Methods 2010; 62: e29-e.
8. Stevens JL, Baker TK,. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14: 162-167.
9. Astashkina A, Mann B, Grainger DW,. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 2012; 134: 82-106.
10. Greer ML, Barber J, Eakins J, Kenna JG,. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 2010; 268: 125-131.
11. LeCluyse EL, Witek RP, Andersen ME, Powers MJ,. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012; 42: 501-548.
12. Sugiyama Y, Yamashita S,. Impact of microdosing clinical study-why necessary and how useful? Adv Drug Deliv Rev 2011; 63: 494-502.
13. Valerio LG Jr,. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009; 241: 356-370.
14. Dixit R, Boelsterli UA,. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 2007; 12: 336-342.
15. Lee WM,. Acetaminophen-related acute liver failure in the United States. Hepatol Res 2008; 38: S3-S8.
16. Ellison CM, Enoch SJ, Cronin MTD,. A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity. Expert Opin Drug Metab Toxicol 2011; 7: 1481-1495.
17. Yan GZ, Generaux CN, Yoon M, et al,. A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab Dispos 2012; 40: 6-17.
18. Caldwell JC, Evans MV, Krishnan K,. Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms. J Toxicol 2012; 2012: 852384.
19. Rostami-Hodjegan A,. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 2012; 92: 50-61.
20. Przybylak KR, Cronin MTD,. In silico models for drug-induced liver injury-current status. Expert Opin Drug Metab Toxicol 2012; 8: 201-217.
21. Remien CH, Adler FR, Waddoups L, Box TD, Sussman NL,. Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death. Hepatology 2012; 56: 727-734.
22. Woodhead JL, Howell BA, Yang Y, et al,. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 2012; 342: 529-540.
23. Howell BA, Yang Y, Kumar R, et al,. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 2012; 39: 527-541.
24. Jaeschke H, McGill MR, Ramachandran A,. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 2012; 44: 88-106.
25. Russmann S, Kullak-Ublick GA, Grattagliano I,. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041-3053.
26. Nadanaciva S, Will Y,. Current concepts in drug-induced mitochondrial toxicity. Curr Protoc Toxicol 2009; Chapter 2: Unit 2.15-Unit 2.15.
27. Ulrich RG, Bacon JA, Branstetter DG, et al,. Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology 1995; 98: 187-198.
28. Vickers AE, Bentley P, Fisher RL,. Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices. Toxicol In Vitro 2006; 20: 1173-1182.
29. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A,. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 2012; 129: 332-345.
30. Dawson SE, Stahl S, Paul N, Barber J, Kenna JGG,. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug induced liver injury in man. Drug Metab Dispos 2012; 40 (1): 130-138. doi: 10.1124/dmd.111.040758.
31. Letellier T, Malgat M, Mazat JP,. Control of oxidative phosphorylation in rat muscle mitochondria: implications for mitochondrial myopathies. Biochim Biophys Acta 1993; 1141: 58-64.
32. Azzone GF, Pozzan T, Massari S,. Proton electrochemical gradient and phosphate potential in mitochondria. Biochim Biophys Acta 1978; 501: 307-316.
33. Desquiret V, Loiseau D, Jacques C, et al,. Dinitrophenol-induced mitochondrial uncoupling in vivo triggers respiratory adaptation in HepG2 cells. Biochim Biophys Acta 2006; 1757: 21-30.
34. Palmeira CM, Moreno AJ, Madeira VM, Wallace KB,. Continuous monitoring of mitochondrial membrane potential in hepatocyte cell suspensions. J Pharmacol Toxicol Methods 1996; 35: 35-43.
35. Berthiaume F, MacDonald AD, Kang YH, Yarmush ML,. Control analysis of mitochondrial metabolism in intact hepatocytes: effect of interleukin-1β and interleukin-6. Metab Eng 2003; 5: 108-123.
36. Brown GC,. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284 (1): 1-13.
37. Nadanaciva S, Rana P, Beeson GC, et al,. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J Bioenerg Biomembr 2012; 44: 421-437.
38. Dykens JA, Jamieson JD, Marroquin LD, et al,. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008; 103: 335-345.
39. Mullen PJ, Zahno A, Lindinger P, et al,. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta 1813; 2011: 2079-2087.
40. Zahno A, Brecht K, Morand R, et al,. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 2011; 81: 432-441.
41. Begriche K, Massart J, Robin M-A, Borgne-Sanchez A, Fromenty B,. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011; 54: 773-794.
42. Hue L, Sobrino F, Bosca L,. Difference in glucose sensitivity of liver glycolysis and glycogen synthesis. Relationship between lactate production and fructose 2,6-bisphosphate concentration. Biochem J 1984; 224: 779-786.
43. Teff KL, Grudziak J, Townsend RR, et al,. Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab 2009; 94: 1562-1569.
44. Moore MC, Pagliassotti MJ, Swift LL, et al,. Disposition of a mixed meal by the conscious dog. Am J Physiol 1994; 266: E666-E675.
45. Lanza-Jacoby S, Stevenson NR, Kaplan ML,. Circadian changes in serum and liver metabolites and liver lipogenic enzymes in ad libitum- and meal-fed, lean and obese Zucker rats. J Nutr 1986; 116: 1798-1809.
46. Raddatz K, Frangioudakis G, Diakanastasis B, Liao BM, Leitges M, Schmitz-Peiffer C,. Deletion of protein kinase Cε in mice has limited effects on liver metabolite levels but alters fasting ketogenesis and gluconeogenesis. Diabetologia 2012; 55: 2789-2793.
47. Mingatto FE, Maioli MA, Bracht A, Ishii-Iwamoto EL,. Effects of monocrotaline on energy metabolism in the rat liver. Toxicol Lett 2008; 182: 115-120.
48. Bryson JM, Cooney GJ, Wensley VR, Phuyal JL, Caterson ID,. The effects of the inhibition of fatty acid oxidation on pyruvate dehydrogenase complex activity in tissues of lean and obese mice. Int J Obes Relat Metab Disord J Int Assoc Study Obes 1996; 20: 738-744.
49. Agius L, Peak M, Sherratt SA,. Differences between human, rat and guinea pig hepatocyte cultures. A comparative study of their rates of beta-oxidation and esterification of palmitate and their sensitivity to R-etomoxir. Biochem Pharmacol 1991; 42: 1711-1715.
50. Holubarsch CJF, Rohrbach M, Karrasch M, et al,. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci Lond Engl 1979 2007; 113: 205-212.
51. Vandercammen A, Van Schaftingen E,. Competitive inhibition of liver glucokinase by its regulatory protein. Eur J Biochem 1991; 200: 545-551.
52. Gould GW, Thomas HM, Jess TJ, Bell GI,. Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry (Mosc) 1991; 30: 5139-5145.
53. Capaldo B, Gastaldelli A, Antoniello S, et al,. Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans. Diabetes 1999; 48: 958-966.
54. Ferrannini E, Wahren J, Felig P, DeFronzo RA,. The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 1980; 29: 28-35.
55. Felig P, Wahren J, Hendler R,. Influence of oral glucose ingestion on splanchnic glucose and gluconeogenic substrate metabolism in man. Diabetes 1975; 24: 468-475.
56. Ainscow EK, Brand MD,. Internal regulation of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. Eur J Biochem 1999; 266: 737-749.
57. Hosey MM, Chatterjee T, Cohen AJ, Stein AL, Kemp RG, Marcus F,. Increased ATP inhibition of liver phosphofructokinase from genetically diabetic mice. Proc Natl Acad Sci U S A 1980; 77: 2497-2499.
58. Denton RM, Randle PJ,. Citrate and the regulation of adipose-tissue phosphofructokinase. Biochem J 1966; 100: 420-423.
59. Nieminen AL, Saylor AK, Herman B, Lemasters JJ,. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. Am J Physiol 1994; 267: C67-C74.
60. Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ,. Hepatic transport of bile salts. Semin Liver Dis 2000; 20: 273-292.
61. Hofmann AF,. Bile Acids: The good, the bad, and the ugly. News Physiol Sci 1999; 14: 24-29.
62. Hofmann AF,. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci J Virtual Libr 2009; 14: 2584-2598.
63. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ,. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118: 422-430.
64. Eloranta JJ, Kullak-Ublick GA,. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 2005; 433: 397-412.
65. Chiang JYL,. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955-1966.
66. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE,. Glyburide-induced hepatitis. Ann Intern Med 1987; 106: 837-839.
67. Van Basten JP, van Hoek B, Zeijen R, Stockbrügger R,. Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992; 40: 305-307.
68. Hofmann AF,. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev 2004; 36: 703-722.
69. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM,. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci 2000; 57: 177-185.
70. Rolo AP, Palmeira CM, Wallace KB,. Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism. Toxicol Lett 2002; 126: 197-203.
71. Makishima M,. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
72. Heuman DM,. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989; 30: 719-730.
73. Heuman DM, Hylemon PB, Vlahcevic ZR,. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J Lipid Res 1989; 30: 1161-1171.
74. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L,. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 1986; 19: 57-69.
75. Falany CN, Johnson MR, Barnes S, Diasio RB,. Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem 1994; 269: 19375-19379.
76. Stieger B,. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011; 201: 205-259.
77. Kis E, Ioja E, Nagy T, Szente L, Herédi-Szabõ K, Krajcsi P,. Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos 2009; 37: 1878-1886.
78. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV,. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 2001; 33: 1223-1231.
79. Hayashi H, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y,. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim Biophys Acta 2005; 1738: 54-62.
80. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ,. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002; 123: 1649-1658.
81. Palmeira CM, Rolo AP,. Mitochondrially-mediated toxicity of bile acids. Toxicology 2004; 203: 1-15.
82. Song P, Zhang Y, Klaassen CD,. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicity in mice. Toxicol Sci 2011; 123: 359-367.
83. Jaeschke H, Williams CD, Ramachandran A, Bajt ML,. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2012; 32: 8-20.
84. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manautou JE,. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 2005; 83: 44-52.
85. Aleksunes LM, Campion SN, Goedken MJ, Manautou JE,. Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci 2008; 104: 261-273.
86. Maddox JF, Amuzie CJ, Li M, et al,. Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A 2010; 73: 58-73.
87. Srinivasan C, Williams WM, Ray MB, Chen TS,. Prevention of acetaminophen-induced liver toxicity by 2(R,S)-n-propylthiazolidine-4(R)- carboxylic acid in mice. Biochem Pharmacol 2001; 61: 245-252.
88. Bourdi M, Masubuchi Y, Reilly TP, et al,. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35: 289-298.
89. Dragomir A-C, Laskin JD, Laskin DL,. Macrophage activation by factors released from acetaminophen-injured hepatocytes: potential role of HMGB1. Toxicol Appl Pharmacol 2011; 253: 170-177.
90. Holt MP, Cheng L, Ju C,. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008; 84: 1410-1421.
91. Laskin DL, Pilaro AM, Ji S,. Potential role of activated macrophages in acetaminophen hepatotoxicity. II. Mechanism of macrophage accumulation and activation. Toxicol Appl Pharmacol 1986; 86: 216-226.
92. Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N,. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 2004; 75: 59-67.
93. Mathew J, Hines JE, James OF, Burt AD,. Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury. J Hepatol 1994; 20: 537-541.
94. DeLeve LD, Wang X, Kaplowitz N, Shulman HM, Bart JA, van der Hoek A,. Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. Biochem Pharmacol 1997; 53: 1339-1345.
95. Antoine DJ, Williams DP, Kipar A, et al,. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009; 112: 521-531.
96. Crofton RW, Diesselhoff-den Dulk MM, van Furth R,. The origin, kinetics, and characteristics of the Kupffer cells in the normal steady state. J Exp Med 1978; 148: 1-17.
97. Bouwens L, Knook DL, Wisse E,. Local proliferation and extrahepatic recruitment of liver macrophages (Kupffer cells) in partial-body irradiated rats. J Leukoc Biol 1986; 39: 687-697.
98. Guilbert LJ, Winkler-Lowen B, Smith A, Branch DR, Garcia-Lloret M,. Analysis of the synergistic stimulation of mouse macrophage proliferation by macrophage colony-stimulating factor (CSF-1) and tumor necrosis factor alpha (TNF-alpha). J Leukoc Biol 1993; 54: 65-72.
99. Van Furth R, Elzenga-Claasen I, van Schadewijk-Nieuwstad M, Diesselhoff-den Dulk MM, Toivonen H, Rytömaa T,. Cell kinetic analysis of a murine macrophage cell line. Eur J Cell Biol 1987; 44: 93-96.
100. Van Furth R, Sluiter W,. Distribution of blood monocytes between a marginating and a circulating pool. J Exp Med 1986; 163: 474-479.
101. Yamamoto T, Naito M, Moriyama H, et al,. Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloromethylene diphosphonate. Am J Pathol 1996; 149: 1271-1286.
102. Bourdi M, Eiras DP, Holt MP, et al,. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol 2007; 20: 208-216.
103. Yee SB, Bourdi M, Masson MJ, Pohl LR,. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol 2007; 20: 734-744.
104. James LP, Kurten RC, Lamps LW, McCullough S, Hinson JA,. Tumour necrosis factor receptor 1 and hepatocyte regeneration in acetaminophen toxicity: a kinetic study of proliferating cell nuclear antigen and cytokine expression. Basic Clin Pharmacol Toxicol 2005; 97: 8-14.
105. DeAngelis RA, Markiewski MM, Taub R, Lambris JD,. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology 2005; 42: 1148-1157.
106. Chen G-Y, Tang J, Zheng P, Liu Y,. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-1725.
107. Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK,. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med Camb Mass 2010; 16: 479-490.
108. Blazka ME, Germolec DR, Simeonova P, Bruccoleri A, Pennypacker KR, Luster MI,. Acetaminophen-induced hepatotoxicity is associated with early changes in NF-kB and NF-IL6 DNA binding activity. J Inflamm 1995; 47: 138-150.
109. Pisetsky DS, Gauley J, Ullal AJ,. HMGB1 and microparticles as mediators of the immune response to cell death. Antioxidants Redox Signal 2011; 15: 2209-2219.
110. Scaffidi P, Misteli T, Bianchi ME,. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
111. Bonaldi T, Talamo F, Scaffidi P, et al,. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-5560.
112. Antoine DJ, Jenkins RE, Dear JW, et al,. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 2012; 56: 1070-1079.
113. Yang R, Zhang S, Cotoia A, Oksala N, Zhu S, Tenhunen J,. High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol 2012; 12: 45.
114. Nishina T, Komazawa-Sakon S, Yanaka S, et al,. Interleukin-11 links oxidative stress and compensatory proliferation. Sci Signal 2012; 5: ra5.
115. Ju C, Reilly T,. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev 2012; 44: 107-115.
116. Gandelman K, Zhu T, Fahmi OA, et al,. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51 (2): 229-236. doi: 10.1177/ 0091270010366445
117. Punt A, Jeurissen SM, Boersma MG, et al,. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. Toxicol Sci 2010; 113: 337-348.
118. Cheng A, Dixon SL,. In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des 2003; 17: 811-823.
119. Ekins S, Williams AJ, Xu JJ,. A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos 2010; 38: 2302-2308.
120. Low Y, Uehara T, Minowa Y, et al,. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol 2011; 24: 1251-1262.
121. Bhattacharya S, Shoda LKM, Zhang Q, et al,. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol 2012; 3: 462.